{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["91"],"submitter":["Wijaya W"],"pubmed_abstract":["<h4>Background</h4>Survivin, an inhibitor of apoptosis protein (IAP), is highly expressed in various cancers but has weak immunogenicity as a self-derived tumour-associated antigen (TAA). OVM-200, a survivin recombinant overlapping peptide (ROP) vaccine, consists of overlapping peptides linked by the target sequence (LRMK) for cathepsin S, preserving T-cell and most antibody epitopes. OVM-200 elicits both cellular and humoral immune responses against survivin-expressing cancer cells. This phase 1a, multicentre, open-label trial (OVM-200-100) evaluates OVM-200 as a therapeutic vaccine in patients with non-small cell lung, ovarian, and prostate cancer. This Phase 1 trial is also the first time the ROP technology platform has been used in human trials.<h4>Methods</h4>Twelve eligible patients "],"journal":["EClinicalMedicine"],"pagination":["103717"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12796589"],"repository":["biostudies-literature"],"pubmed_title":["Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study."],"pmcid":["PMC12796589"],"pubmed_authors":["Tuthill M","Lu W","Forster MD","Finch W","Jiang S","Flynn M","Williams A","Wijaya W","Morris T","Thistlethwaite F"],"additional_accession":[]},"is_claimable":false,"name":"Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study.","description":"<h4>Background</h4>Survivin, an inhibitor of apoptosis protein (IAP), is highly expressed in various cancers but has weak immunogenicity as a self-derived tumour-associated antigen (TAA). OVM-200, a survivin recombinant overlapping peptide (ROP) vaccine, consists of overlapping peptides linked by the target sequence (LRMK) for cathepsin S, preserving T-cell and most antibody epitopes. OVM-200 elicits both cellular and humoral immune responses against survivin-expressing cancer cells. This phase 1a, multicentre, open-label trial (OVM-200-100) evaluates OVM-200 as a therapeutic vaccine in patients with non-small cell lung, ovarian, and prostate cancer. This Phase 1 trial is also the first time the ROP technology platform has been used in human trials.<h4>Methods</h4>Twelve eligible patients ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T05:36:08.34Z","creation":"2026-06-09T03:07:47.425Z"},"accession":"S-EPMC12796589","cross_references":{"pubmed":["41536940"],"doi":["10.1016/j.eclinm.2025.103717"]}}